What is Wedbush's Forecast for CATX Q2 Earnings?

Key Points

• Wedbush forecasts that Perspective Therapeutics, Inc. (NYSE:CATX) will report a Q2 2026 earnings per share (EPS) of ($0.38), maintaining an "Outperform" rating with a price target of $11.00.
• Despite a mixed range of price targets from various brokerages, the consensus price target for CATX currently stands at $12.56, reflecting a majority "buy" rating from analysts.
• CATX shares recently traded at $3.73, and the company has seen significant institutional interest, with hedge funds owning approximately 54.66% of the stock.

Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Equities research analysts at Wedbush issued their Q2 2026 earnings per share (EPS) estimates for shares of Perspective Therapeutics in a report issued on Wednesday, August 13th. Wedbush analyst D. Nierengarten forecasts that the company will post earnings per share of ($0.38) for the quarter. Wedbush currently has a "Outperform" rating and a $11.00 target price on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share. Wedbush also issued estimates for Perspective Therapeutics' Q3 2026 earnings at ($0.38) EPS and Q4 2026 earnings at ($0.39) EPS.

CATX has been the subject of a number of other research reports. Royal Bank Of Canada raised Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and lifted their target price for the stock from $15.00 to $16.00 in a report on Tuesday, June 3rd. B. Riley reissued a "buy" rating and issued a $12.00 target price (up previously from $9.00) on shares of Perspective Therapeutics in a report on Monday, June 23rd. Truist Financial reduced their target price on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Finally, Lifesci Capital raised Perspective Therapeutics to a "strong-buy" rating in a report on Saturday, July 12th. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $12.56.

Perspective Therapeutics Stock Down 7.3%

CATX stock traded down $0.27 on Friday, reaching $3.42. 1,108,384 shares of the company traded hands, compared to its average volume of 948,162. Perspective Therapeutics has a one year low of $1.60 and a one year high of $16.55. The firm has a fifty day simple moving average of $3.77 and a 200-day simple moving average of $2.96.

Institutional Trading of Perspective Therapeutics

Several hedge funds have recently bought and sold shares of CATX. JPMorgan Chase & Co. grew its holdings in Perspective Therapeutics by 498.3% during the fourth quarter. JPMorgan Chase & Co. now owns 149,045 shares of the company's stock valued at $475,000 after purchasing an additional 124,133 shares during the period. Wells Fargo & Company MN grew its holdings in Perspective Therapeutics by 45.7% during the fourth quarter. Wells Fargo & Company MN now owns 26,462 shares of the company's stock valued at $84,000 after purchasing an additional 8,294 shares during the period. Mariner LLC bought a new stake in Perspective Therapeutics during the fourth quarter valued at about $150,000. Walleye Capital LLC grew its holdings in Perspective Therapeutics by 2,526.2% during the fourth quarter. Walleye Capital LLC now owns 475,792 shares of the company's stock valued at $1,518,000 after purchasing an additional 457,675 shares during the period. Finally, Jump Financial LLC bought a new stake in Perspective Therapeutics during the fourth quarter valued at about $688,000. Institutional investors own 54.66% of the company's stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.